Psychopharmacology Bulletin VOL 37 Supplement No. 1
Advances in Recognition and Treatment of Social Anxiety Disorder: A 10-Year Retrospective
By Murray B. Stein, MD, FRCPC
Advancing the Treatment of Mood and Anxiety Disorders: The First 10 Years’ Experience with Paroxetine
By Charles B. Nemeroff, MD, PhD
Clinical Management of Perinatal Depression: Focus on Paroxetine
By D. Jeffrey Newport, MD, MSCR, MDiv, and Zachary N. Stowe, MD
Efficacy and Tolerability of Controlled-Release Paroxetine
By Robert N. Golden, MD
In Vivo Neuroimaging Correlates of the Efficacy of Paroxetine in the Treatment of Mood and Anxiety Disorders
By Clinton Kilts, PhD
Neuropharmacology of Paroxetine
By Michael J. Owens, PhD, and Charles B. Nemeroff, MD, PhD
Obsessive-Compulsive Disorder: Implications of the Efficacy of an SSRI, Paroxetine
By Philip T. Ninan, MD
Paroxetine Treatment of Depression in Late Life
By Charles F. Reynolds III, MD
Paroxetine Treatment of Generalized Anxiety Disorder
By David V. Sheehan, MD, MBA, and C. Gloria Mao, PharmD
Paroxetine Treatment of Major Depressive Disorder
By Martin B. Keller, MD
Paroxetine Treatment of Mood and Anxiety Disorders in Children and Adolescents
By Karen Dineen Wagner, MD, PhD
Paroxetine Treatment of Mood Disorders in Women: Premenstrual Dysphoric Disorder and Hot Flashes
By Kimberly A. Yonkers, MD
Paroxetine Use in Medically Ill Patients
By Steven Stout, MD, PhD, Wendy I. Somerset, MD, Andrew Miller, MD, and Dominique L. Musselman, MD, MS
Pharmacokinetics, Drug Interactions, and Tolerability of Paroxetine and Paroxetine CR
By C. Lindsay DeVane, PharmD
Treatment of Panic Disorder: Focus on Paroxetine
By Mark H. Pollack, MD and Alicia C. Doyle, BA
Treatment of Posttraumatic Stress Disorder: The Impact of Paroxetine
By Jonathan R.T. Davidson, MD